DLG4 and Parkinson disease: , GsRb1 showed increased postsynaptic density protein 95 (PSD-95) expression in an α-Syn-dependent manner in vitro and in vivo, slowed memory loss and long-term potentiation (LTP) induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (which induces typical parkinsonism in both humans and primates), whereas GsRb1 alleviated glutamate excitotoxicity by upregulating glutamate transporter expression and treated memory impairment and dyskinesia in PD patients with PD (Zhang YL.